# Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

> **NCT04545008** · PHASE1 · TERMINATED · sponsor: **Prisma Health-Upstate** · enrollment: 2 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Famotidine
- **DRUG:** N-Acetyl cysteine

## Key facts

- **NCT ID:** NCT04545008
- **Lead sponsor:** Prisma Health-Upstate
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-20
- **Primary completion:** 2021-06-02
- **Final completion:** 2021-06-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study was stopped due to poor accrual.
- **Last updated:** 2022-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04545008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04545008, "Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04545008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*